While in Sydney last month, Anatara Lifesciences (ASX:ANR) CEO Steve Lydeamore sat down with Anna Napoli at Finance News Network, Australia's largest provider of online business and finance news.

Steve sat down with Anna to talk about our upcoming clinical studies for our lead Gastrointestinal Reprogramming dietary supplement product candidate for Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD). Steve discusses the completion of our pre-clinical in vitro proof of concept studies, which demonstrated our products' ability to address three shared characteristics of these conditions - inflammation, impaired intestinal barrier function and mucosal damage. The timeframe for partnering our dietary supplement product candidate is 18 to 24 months.

To view the interview, please visit:
http://www.abnnewswire.net/lnk/ZS6SD794

To view the latest Corporate Fact Sheet for further information on Anatara Lifesciences, please visit:
http://abnnewswire.net/lnk/G465OU6A


About Anatara Lifesciences Ltd

Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.

    

Contact

General inquiries
Steven Lydeamore
CEO
Anatara Lifesciences
T: +61-438-027-172
E: slydeamore@anatara.com

Media inquiries:
Jane Lowe
Managing Director
IR Department
T: +61-411-117-774
E: jane.lowe@irdepartment.com.au




Related Companies

Anatara Lifesciences Ltd


Related Industry Topics:
Biotech Drugs & OTC Health & Pharm General